SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Rabindranath Tagore Synthetic CCD

PatientRabindranath Tagore
Date of birth1946-05-07
IdentifiersMRN HR-ET021-SYN; SSN (made up) 000-21-9325
Document date2026-11-01
AuthorArvind Sengupta, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

New-patient visit for a weak stream, straining, and frequent urination at night, with a feeling that the bladder does not empty. Concerns: A weak stream, straining, dribbling, and getting up four times a night for months; lately he passes only small amounts and feels his bladder never empties; Since a severe urinary infection in the hills five months ago he has not felt well; he wants to keep writing and teaching; He fears an operation more than he fears his illness, and wants to know every gentler choice before any surgery is decided. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Tamsulosin 0.4 mg oral capsule, one capsule by mouth at bedtimeOne capsule by mouth 30 minutes after the evening meal, at bedtimeOral route2026-02-17activeS
Finasteride 5 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-03-03activeS
Polyethylene glycol 3350, 17 g in water once daily as needed for constipation17 g dissolved in a glass of water once daily if no bowel movement for two daysOral route2026-02-17activeS
Ceftriaxone 1 g intramuscularly, one dose in clinicOne dose of 1 g intramuscularly after culturesIntramuscular route2026-03-17 to 2026-03-17completedS
Cefpodoxime 200 mg oral tablet, one tablet by mouth twice daily for 6 daysOne tablet by mouth twice daily with food, to complete 7 days of treatmentOral route2026-03-17 to 2026-03-23completedS
Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for fever or discomfortTwo tablets every 6 hours as needed; no more than 3 g a dayOral route2026-03-17 to 2026-03-23completedS

Procedures

ProcedureDatesStatusEvidence
Indwelling urethral catheter inserted (16 French, 10 mL balloon) with a leg bag and night bag; 680 mL drained; observed for two hours for post-obstructive diuresis, which did not occur2026-02-17 to 2026-02-17completedS
Ultrasound of both kidneys and the bladder: no hydronephrosis; kidneys normal in size; bladder wall trabeculated, catheter balloon in place; prostate about 85 mL with a modest median lobe2026-03-03 to 2026-03-03completedS
Change of urethral catheter before cultures for a febrile catheter-associated infection; urine culture taken from the new catheter2026-03-17 to 2026-03-17completedS
Trial without catheter after six weeks of tamsulosin: catheter removed in the early morning; voided small amounts; bladder scan 420 mL; catheter replaced2026-03-31 to 2026-03-31completedS
Second trial without catheter after four months of finasteride with tamsulosin: catheter removed in the early morning; voided 240 mL and 210 mL; bladder scan 150 mL; catheter left out2026-07-14 to 2026-07-14completedS

Immunizations

DateVaccineStatusEvidence
2025-10-14High-dose influenza vaccine, 2025-2026 seasoncompletedS
2026-06-09Respiratory syncytial virus vaccine (adjuvanted), single dosecompletedS
2026-06-09Pneumococcal conjugate vaccine PCV20completedS
2026-06-09Recombinant zoster vaccine, dose 1 of 2completedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
Late 1937Loss of consciousness, comatose and near death for a time; the illness is not characterized further in the cited sourceD (CLM-0005)
15 September 1940Severe lower abdominal pain with a severe urinary tract infection while visiting the hills at Kalimpong; brought back unconscious to Calcutta for treatmentD (CLM-0006)

Family History

RelativeConditionAge at deathEvidence
natural daughterTuberculosis in young adulthood; died before him (cause of death not recorded in the cited source)D (CLM-0016)

Health Concerns

ConcernStatusEvidence
A weak stream, straining, dribbling, and getting up four times a night for months; lately he passes only small amounts and feels his bladder never emptiesactiveS
Since a severe urinary infection in the hills five months ago he has not felt well; he wants to keep writing and teachingactiveS
He fears an operation more than he fears his illness, and wants to know every gentler choice before any surgery is decidedactiveS

Assessment

Most recent measures: Symptom score [AUASI] 13 on 2026-07-14; If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that [IPSS] 3 on 2026-07-14; US Urinary bladder Volume post void 150 on 2026-07-14; Leukocytes [#/area] in Urine sediment by Microscopy high power field 60 on 2026-03-17; Hemoglobin [Mass/volume] in Blood 13.4 on 2026-03-17; Sodium [Moles/volume] in Serum or Plasma 140 on 2026-07-14; Potassium [Moles/volume] in Serum or Plasma 4.5 on 2026-07-14; Carbon dioxide, total [Moles/volume] in Serum or Plasma 25 on 2026-07-14; Urea nitrogen [Mass/volume] in Serum or Plasma 18 on 2026-07-14; Creatinine [Mass/volume] in Serum or Plasma 1.12 on 2026-07-14; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 66 on 2026-07-14; Glucose [Mass/volume] in Serum or Plasma 93 on 2026-07-14; Prostate specific Ag [Mass/volume] in Serum or Plasma 2.6 on 2026-07-14; Prostate Volume by derived from height, width and length (US) 85 on 2026-03-03; Leukocytes [#/volume] in Blood by Automated count 13.8 on 2026-03-17; Total score [Mini-Cog] 4 on 2026-03-31; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 on 2026-06-09 [S]

Strengths and supports: Supports: his writing, his students and colleagues, his family and helpers, and a daily practice of prayer and quiet; no firearms in the home [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Benign prostatic hyperplasia with severe lower urinary tract symptoms (IPSS 26) and bladder outlet obstruction: prostate about 85 mL on ultrasound, smooth and benign on examination, PSA 4.9 ng/mL (PSA density 0.06)activeconfirmed N40.1S — Synthetic modern diagnosis linked to the retrospective enlarged-prostate reading of his last illness; the conflicting cancer claim is not adopted.
Urinary retention with severe lower urinary tract symptoms (bladder scan 640 mL after voiding) and a raised creatinine, cause under evaluationresolvedconfirmed R33.9S — Synthetic presenting concern at the index visit, superseded by the diagnosis of benign prostatic hyperplasia with chronic retention at the two-week visit.
Chronic urinary retention from bladder outlet obstruction, low risk once drained (no hydronephrosis; creatinine normal after drainage), managed with an indwelling urethral catheterresolvedconfirmed R33.8S — Synthetic diagnosis; resolved after a successful second trial without catheter.
Catheter-associated urinary tract infection with fever, without sepsis; resolvedresolvedconfirmed T83.511AS — Synthetic complication of the synthetic catheter at an unscheduled visit; it echoes, without asserting, the urinary infections of his documented last illness.
Mild frailty (Clinical Frailty Scale 5): slow gait (Timed Up and Go 15 seconds), needs help with heavy housework and travel; cognition normal (Mini-Cog 4)activeconfirmed R54S — Synthetic geriatric assessment before the surgical decision.

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-02-17Symptom score [AUASI]26{score}S
2026-02-17If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that [IPSS]5{score}S
2026-02-17US Urinary bladder Volume post void640mL<=100 mLHighS
2026-02-17Leukocytes [#/area] in Urine sediment by Microscopy high power field3/[HPF]<=5 /[HPF]NormalS
2026-02-17Hemoglobin [Mass/volume] in Blood13.6g/dL13.2-16.6 g/dLNormalS
2026-02-17Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-02-17Potassium [Moles/volume] in Serum or Plasma4.7mmol/L3.5-5.1 mmol/LNormalS
2026-02-17Carbon dioxide, total [Moles/volume] in Serum or Plasma23mmol/L22-29 mmol/LNormalS
2026-02-17Urea nitrogen [Mass/volume] in Serum or Plasma27mg/dL8-23 mg/dLHighS
2026-02-17Creatinine [Mass/volume] in Serum or Plasma1.42mg/dL0.74-1.35 mg/dLHighS
2026-02-17Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M50mL/min/{1.73_m2}>=60 mL/min/1.73 m²LowS
2026-02-17Glucose [Mass/volume] in Serum or Plasma97mg/dL70-99 mg/dLNormalS
2026-02-17Prostate specific Ag [Mass/volume] in Serum or Plasma4.9ng/mLAge-specific upper limit 6.5 ng/mL for 70 to 79 years; halve the expected value on finasterideNormalS
2026-03-03Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
2026-03-03Potassium [Moles/volume] in Serum or Plasma4.4mmol/L3.5-5.1 mmol/LNormalS
2026-03-03Carbon dioxide, total [Moles/volume] in Serum or Plasma25mmol/L22-29 mmol/LNormalS
2026-03-03Urea nitrogen [Mass/volume] in Serum or Plasma18mg/dL8-23 mg/dLNormalS
2026-03-03Creatinine [Mass/volume] in Serum or Plasma1.18mg/dL0.74-1.35 mg/dLNormalS
2026-03-03Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M63mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-03-03Glucose [Mass/volume] in Serum or Plasma94mg/dL70-99 mg/dLNormalS
2026-03-03Prostate Volume by derived from height, width and length (US)85mL<=30 mLHighS
2026-03-17Leukocytes [#/volume] in Blood by Automated count13.810*3/uL3.4-9.6 10*3/uLHighS
2026-03-17Hemoglobin [Mass/volume] in Blood13.4g/dL13.2-16.6 g/dLNormalS
2026-03-17Sodium [Moles/volume] in Serum or Plasma136mmol/L135-145 mmol/LNormalS
2026-03-17Potassium [Moles/volume] in Serum or Plasma4.5mmol/L3.5-5.1 mmol/LNormalS
2026-03-17Carbon dioxide, total [Moles/volume] in Serum or Plasma23mmol/L22-29 mmol/LNormalS
2026-03-17Urea nitrogen [Mass/volume] in Serum or Plasma25mg/dL8-23 mg/dLHighS
2026-03-17Creatinine [Mass/volume] in Serum or Plasma1.31mg/dL0.74-1.35 mg/dLNormalS
2026-03-17Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M55mL/min/{1.73_m2}>=60 mL/min/1.73 m²LowS
2026-03-17Glucose [Mass/volume] in Serum or Plasma112mg/dL70-99 mg/dLHighS
2026-03-17Leukocytes [#/area] in Urine sediment by Microscopy high power field60/[HPF]<=5 /[HPF]HighS
2026-03-31US Urinary bladder Volume post void420mL<=100 mLHighS
2026-03-31Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-03-31Potassium [Moles/volume] in Serum or Plasma4.6mmol/L3.5-5.1 mmol/LNormalS
2026-03-31Carbon dioxide, total [Moles/volume] in Serum or Plasma24mmol/L22-29 mmol/LNormalS
2026-03-31Urea nitrogen [Mass/volume] in Serum or Plasma19mg/dL8-23 mg/dLNormalS
2026-03-31Creatinine [Mass/volume] in Serum or Plasma1.16mg/dL0.74-1.35 mg/dLNormalS
2026-03-31Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M64mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-03-31Glucose [Mass/volume] in Serum or Plasma95mg/dL70-99 mg/dLNormalS
2026-03-31Total score [Mini-Cog]4{score}S
2026-06-09Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S
2026-07-14US Urinary bladder Volume post void150mL<=100 mLHighS
2026-07-14Symptom score [AUASI]13{score}S
2026-07-14If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that [IPSS]3{score}S
2026-07-14Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
2026-07-14Potassium [Moles/volume] in Serum or Plasma4.5mmol/L3.5-5.1 mmol/LNormalS
2026-07-14Carbon dioxide, total [Moles/volume] in Serum or Plasma25mmol/L22-29 mmol/LNormalS
2026-07-14Urea nitrogen [Mass/volume] in Serum or Plasma18mg/dL8-23 mg/dLNormalS
2026-07-14Creatinine [Mass/volume] in Serum or Plasma1.12mg/dL0.74-1.35 mg/dLNormalS
2026-07-14Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M66mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-07-14Glucose [Mass/volume] in Serum or Plasma93mg/dL70-99 mg/dLNormalS
2026-07-14Prostate specific Ag [Mass/volume] in Serum or Plasma2.6ng/mLAge-specific upper limit 6.5 ng/mL for 70 to 79 years; halve the expected value on finasterideNormalS

Social History

Vital Signs

DateMeasureValueUnitProvenance
2026-02-17Body height183cmS
2026-02-17Body weight66kgS
2026-02-17Body mass index (BMI) [Ratio]19.7kg/m2S
2026-02-17Systolic blood pressure138mm[Hg]S
2026-02-17Diastolic blood pressure78mm[Hg]S
2026-02-17Heart rate76/minS
2026-02-17Respiratory rate16/minS
2026-02-17Body temperature36.7CelS
2026-02-17Oxygen saturation in Arterial blood by Pulse oximetry97%S
2026-03-03Body height183cmS
2026-03-03Body weight65.8kgS
2026-03-03Body mass index (BMI) [Ratio]19.6kg/m2S
2026-03-03Systolic blood pressure132mm[Hg]S
2026-03-03Diastolic blood pressure76mm[Hg]S
2026-03-03Heart rate72/minS
2026-03-03Respiratory rate16/minS
2026-03-03Body temperature36.6CelS
2026-03-03Oxygen saturation in Arterial blood by Pulse oximetry97%S
2026-03-17Body height183cmS
2026-03-17Body weight65.1kgS
2026-03-17Body mass index (BMI) [Ratio]19.4kg/m2S
2026-03-17Systolic blood pressure118mm[Hg]S
2026-03-17Diastolic blood pressure68mm[Hg]S
2026-03-17Heart rate98/minS
2026-03-17Respiratory rate18/minS
2026-03-17Body temperature38.4CelS
2026-03-17Oxygen saturation in Arterial blood by Pulse oximetry96%S
2026-03-31Body height183cmS
2026-03-31Body weight65.3kgS
2026-03-31Body mass index (BMI) [Ratio]19.5kg/m2S
2026-03-31Systolic blood pressure128mm[Hg]S
2026-03-31Diastolic blood pressure72mm[Hg]S
2026-03-31Heart rate74/minS
2026-03-31Respiratory rate16/minS
2026-03-31Body temperature36.6CelS
2026-03-31Oxygen saturation in Arterial blood by Pulse oximetry97%S
2026-04-28Body height183cmS
2026-04-28Body weight65.6kgS
2026-04-28Body mass index (BMI) [Ratio]19.6kg/m2S
2026-04-28Systolic blood pressure130mm[Hg]S
2026-04-28Diastolic blood pressure74mm[Hg]S
2026-04-28Heart rate72/minS
2026-04-28Respiratory rate16/minS
2026-04-28Body temperature36.6CelS
2026-04-28Oxygen saturation in Arterial blood by Pulse oximetry97%S
2026-06-09Body height183cmS
2026-06-09Body weight66kgS
2026-06-09Body mass index (BMI) [Ratio]19.7kg/m2S
2026-06-09Systolic blood pressure132mm[Hg]S
2026-06-09Diastolic blood pressure76mm[Hg]S
2026-06-09Heart rate70/minS
2026-06-09Respiratory rate16/minS
2026-06-09Body temperature36.7CelS
2026-06-09Oxygen saturation in Arterial blood by Pulse oximetry97%S
2026-07-14Body height183cmS
2026-07-14Body weight66.2kgS
2026-07-14Body mass index (BMI) [Ratio]19.8kg/m2S
2026-07-14Systolic blood pressure130mm[Hg]S
2026-07-14Diastolic blood pressure74mm[Hg]S
2026-07-14Heart rate70/minS
2026-07-14Respiratory rate16/minS
2026-07-14Body temperature36.6CelS
2026-07-14Oxygen saturation in Arterial blood by Pulse oximetry97%S

Encounters

DatePurposeStatusProvenance
2026-02-17New-patient visit for a weak stream, straining, and frequent urination at night, with a feeling that the bladder does not emptyfinishedS
2026-03-03Two-week review with kidney and bladder ultrasound results and urology consultationfinishedS
2026-03-31Six-week review with a trial without catheter and a geriatric assessmentfinishedS
2026-04-28Ten-week review: shared decision about treatment and goals of carefinishedS
2026-07-14Five-month review with a planned second trial without catheterfinishedS
2026-03-17Same-day sick visit for fever with a urinary catheterfinishedS
2026-06-09Subsequent annual wellness visitfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Evaluation: IPSS with the quality-of-life question, bladder scan for post-void residual, urinalysis and urine culture, blood count, creatinine and electrolytes, digital rectal examination, and a kidney and bladder ultrasound for obstruction; a frequency-volume chart once voidingcompletedGL-AUA-BPH-2021, GL-AUA-CUR-2017, GL-CMID-2026S
PSA only after shared decision-making: it helps estimate prostate size and choose treatment; screening for prostate cancer is not recommended at his age, and he would not want treatment for a slow-growing cancer; drawn before the catheter is placed, because retention and catheters raise itcompletedGL-AUA-BPH-2021, GL-USPSTF-PROSTATE-2018, GL-CMID-2026S
Indwelling urethral catheter to drain the bladder, with a closed drainage system, the bag below the bladder, daily washing with soap and water, no routine antibiotics or bladder washouts, no treatment of bacteria in the urine without symptoms, a change every four weeks, and same-day review for fever, pain, blood, or a blocked cathetercompletedGL-IDSA-CAUTI-2009, GL-AUA-CUR-2017S
Tamsulosin 0.4 mg at bedtime for at least three days and usually several weeks before a trial without catheter; fall precautions: take it after the evening meal, rise slowly, sit to pass urine at night, and use a night lightcompletedGL-AUA-BPH-2021, GL-BEERS-2023S
Urology consultation for chronic urinary retention with a raised creatinine: confirm the cause, judge the risk, plan the trial without catheter, advise on a 5-alpha-reductase inhibitor, and set out the procedures that suit a frail 79-year-old who wants to avoid an operationcompletedGL-AUA-BPH-2021, GL-AUA-BPH-2023, GL-CMID-2026, GL-AUA-CUR-2017S
Medication review with the AGS Beers Criteria: avoid anticholinergic drugs for bladder symptoms while in retention, first-generation antihistamines, and benzodiazepines; avoid nonselective alpha-blockers; review his herbal preparation with the pharmacist for interactions and unlabeled ingredientscompletedGL-BEERS-2023, GL-AYUR-METALS-2008S
Monitor on the CMID and AUA schedule: IPSS at every visit once voiding; post-void residual with each trial without catheter and after it; creatinine with retention; PSA at baseline and six months after starting finasteride, doubled for interpretation; response to tamsulosin at four to twelve weeks and to finasteride at three to six monthscompletedGL-AUA-BPH-2021, GL-AUA-BPH-2023, GL-CMID-2026S
Geriatric assessment before any surgical decision: frailty, gait and falls, orthostatic blood pressure on tamsulosin, cognition, mood, delirium risk, nutrition, and what matters most to himcompletedGL-BEERS-2023, GL-AUA-BPH-2021S
Finasteride 5 mg daily for the 85 mL prostate, with a new PSA baseline after six months (measured value doubled for interpretation); trial without catheter after about six weeks of tamsulosin, once any infection is treatedcompletedGL-AUA-BPH-2021, GL-AUA-BPH-2023, GL-CMID-2026S
Surgical options counseled after the failed trial without catheter: laser enucleation (HoLEP) recommended for an 85 mL prostate with refractory retention; transurethral resection and simple prostatectomy as alternatives; prostatic artery embolization under local anesthesia as a less invasive option with less durable results; prostatic urethral lift and water vapor therapy less suitable for this size, median lobe, and retention; each weighed against his frailty, delirium risk, and wishescompletedGL-AUA-BPH-2021, GL-AUA-BPH-2023, GL-CMID-2026, GL-BEERS-2023S
His decision, in his own terms: defer any operation or procedure; keep the catheter, changed every four weeks, with tamsulosin and finasteride; a second trial without catheter after three to four months of finasteride; reconsider prostatic artery embolization, then laser enucleation, if that fails or if infections recur, bleeding, stones, or kidney harm develop; continue his herbal preparation after the pharmacist's reviewcompletedGL-AUA-BPH-2021, GL-AUA-BPH-2023, GL-CMID-2026, GL-AUA-CUR-2017S

Goals

GoalTargetStatusOutcomeProvenance
Bladder drained and kidney function back to normal within two weeks2026-03-03completedCreatinine 1.42 mg/dL at presentation, 1.18 mg/dL after two weeks of drainage; no hydronephrosisS
No catheter-associated infection, or prompt treatment if one occurs2026-03-31completedOne febrile catheter-associated infection at four weeks, treated in clinic for 7 days without admission; resolvedS
A treatment decision that he understands and that fits his values, after a geriatric assessment, by about ten weeks2026-04-28completedChose to continue the catheter with tamsulosin and finasteride and to try again without the catheter after three to four months, deferring surgery; recorded in his own wordsS
Voiding without a catheter, with a post-void residual under 300 mL, by about five months2026-07-14completedSecond trial without catheter succeeded: residual 150 mL, IPSS 13S
Goals of care and a health care agent recorded2026-06-09completedGoals of care discussed at the ten-week visit; health care agent named and his wishes recorded at the wellness visitS

Functional Status

Mental Status